...Micromet AG to the U.S. in 2006. Pieris...

...the boards of Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Pieris...

...a 2017 immuno-oncology deal Servier did with Pieris...

...hired Ingmar Bruns as CMO. Bruns, who succeeds Yaping Shou, was SVP and head of clinical development at Pieris...

...VP and head of clinical development at Agios Pharmaceuticals Inc. (NASDAQ:AGIO). Reine was CFO at Pieris...

...cell therapies. A February 2018 deal with Pieris Pharmaceuticals Inc. gave Seattle Genetics access to Pieris’...
...platform to develop bispecific candidates to treat solid tumors and blood cancers. The deal combines Pieris’...
...AG (Xetra:BAYN), Leverkusen, Germany bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. ISA Pharmaceuticals B.V., Leiden, Netherlands Pieris...

...Development and Manufacturing Scott Lauder to chief technology officer. Knopf was SVP and CBO at Pieris...

...bispecific compounds that target 4-1BB on T cells and a protein on tumor cell surfaces. Pieris...
...Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE: PFE), New York, N.Y. Pieris...
...plc Bristol-Myers Squibb Co. Elpiscience Biopharmaceuticals Co. Ltd. Enumeral Biomedical Holdings Inc. Harvard Medical School Inhibrx LLC Merck & Co. Inc. Pfizer Inc. Pieris...

...Anticalin company Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) raised $50.6 million through the sale of 6.3 million shares...
...$9.45 on Feb 13, before the offering was proposed. Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), Boston, Mass. Shannon Lehnbeuter Pieris...

...Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) partnered to develop bispecific...
...bispecific candidates to treat solid tumors and blood cancers. The partners will develop candidates using Pieris'...
...Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), Boston, Mass. Business: Cancer Allison Johnson Pieris...